Conditions: Type 2 Diabetes
Keywords: type 2 diabetes obesity
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 24
Healthy volunteers: no

Brief summary:
Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss.

The purpose of this study is to determine if the addition of Exenatide to diabetic patients will reduce the requirements of insulin particularly the short acting insulin. Exenatide may also lead to decreased inflammation by virtue of better glycemic control and weight loss, or an independent effect.

Detailed description:

Arms:
arm 1: exenatide 5 mcg arm 2: exenatide 10 mcg arm 3: placebo

Interventions: intervention 1: exenatide 5 mcg intervention 2: exenatide 10 mcg intervention 3: placebo
Intervention descriptions: intervention 1: exenatide 5 mcg intervention 2: exenatide 10 mcg intervention 3: saline sq

Protocol document: